Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Abramson, Jeremy ^{[1
]}

Palomba, M. Lia ^{[2
]}

Gordon, Leo ^{[3
]}

Lunning, Matthew ^{[4
]}

Wang, Michael ^{[5
]}

Arnason, Jon ^{[6
]}

Mehta, Amitkumar ^{[7
]}

Purev, Enkhtsetseg ^{[8
]}

Maloney, David ^{[9
]}

Andreadis, Charalambos ^{[10
]}

Sehgal, Alison ^{[11
]}

Solomon, Scott ^{[12
]}

Ghosh, Nilanjan ^{[13
]}

Albertson, Tina ^{[14
]}

Garcia, Jacob ^{[14
]}

Kostic, Aria ^{[14
]}

Li, Daniel ^{[14
]}

Kim, Yeonhee ^{[14
]}

Siddiqi, Tanya ^{[15
]}

机构：

[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[4] Univ Nebraska Med Ctr, Omaha, NE USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Colorado, Sch Med, Aurora, CO USA

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Univ Calif San Francisco, San Francisco, CA 94143 USA

[11] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[12] Northside Hosp, Canc Inst, Immunotherapy Program, Atlanta, GA USA

[13] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[14] Juno Therapeut, Seattle, WA USA

[15] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

976

引用

页码：215 / 215

页数：1

共 50 条

[41] COST EFFECTIVENESS OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL TREATMENT LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE (2L) TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN SWITZERLAND
Deger, K.
Oniangue-Ndza, C.
Elsada, A.
Litkiewicz, M.
Villalobos, Franco C.
Sorensen, S.
VALUE IN HEALTH, 2023, 26 (12) : S152 - S153
[42] Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
Lee, Dasom
Sworder, Brian J.
Stepan, Lara
Okal, Abood
Huang, Chang-Pin
Kang, Xiaoman
Hamilton, James
Macaulay, Charles
Olsen, Mari
Liu, Chih Long
Diehn, Maximilian
Peiser, Leanne
Kurtz, David
Alizadeh, Ash A.
BLOOD, 2024, 144 : 3412 - 3412
[43] Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
Sehgal, Alison R.
Hildebrandt, Gerhard
Ghosh, Nilanjan
Godwin, John E.
Wagner-Johnston, Nina D.
Hoda, Daanish
Licitra, Edward J.
Munoz, Javier
Trede, Nikolaus S.
Wang, Lei
Thorpe, Jerill
Gordon, Leo, I
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study
Sehgal, Alison R.
Godwin, John
Pribble, John
Wang, Lei
Thorpe, Jerill
Hildebrandt, Gerhard C.
BLOOD, 2019, 134
[45] Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001
Palomba, Maria Lia
Siddiqi, Tanya
Gordon, Leo I.
Kamdar, Manali
Lunning, Matthew A.
Hirayama, Alexandre V.
Abramson, Jeremy S.
Arnason, Jon E.
Ghosh, Nilanjan
Mehta, Amitkumar
Andreadis, Charalambos
Solomon, Scott R.
Kostic, Ana
Singh, Ashvin
Espinola, Ricardo
Peng, Lily
Ogasawara, Ken
Chattin, Amy
Wang, Michael L.
BLOOD, 2023, 142
[46] Impact of lisocabtagene maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: TRANSCEND NHL 001 (NCT02631044)
Patrick, D.
Powers, A.
Jun, M. Parisi
Kim, Y.
Garcia, J.
Dehner, C.
Maloney, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 220 - 221
[47] Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)
Cartron, Gillaume
Garcia-Sancho, Alejandro Martin
Reguera, Juan Luis
Dahiya, Saurabh
Guo, Shien
Shi, Ling
Eliason, Laurie
Kumar, Jinender
Farazi, Thalia
Fasan, Omotayo
Izutsu, Koji
BLOOD, 2023, 142
[48] Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL
Wang, Michael L.
Gordon, Leo I.
Hirayama, Alexandre V.
Lunning, Matthew A.
Shi, Ling
Guo, Shien
Kostic, Ana
Eliason, Laurie
Kumar, Jinender
Palomba, Maria Lia
BLOOD, 2023, 142
[49] Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
Wang, Michael
Siddiqi, Tanya
Gordon, Leo I.
Kamdar, Manali
Lunning, Matthew
Hirayama, Alexandre V.
Abramson, Jeremy S.
Arnason, Jon
Ghosh, Nilanjan
Mehta, Amitkumar
Andreadis, Charalambos
Solomon, Scott R.
Kostic, Ana
Dehner, Christine
Espinola, Ricardo
Peng, Lily
Ogasawara, Ken
Chattin, Amy
Eliason, Laurie
Palomba, M. Lia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (10) : 1146 - 1157
[50] Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study
Wierda, William G.
Maloney, David G.
Kenderian, Saad S.
Brander, Danielle M.
Papp, Eniko
Ray, Pradipta
Okal, Abood
Perna, Serena K.
Tuazon, Sherilyn A.
Ou, San-San
Ansari, Sahar
Rane, Neha
Shamsuzzaman, Md
Ananthakrishnan, Revathi
Jaskiewicz, Adam
Peiser, Leanne
Siddiqi, Tanya
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S346 - S346

← 1 2 3 4 5 →